Study of AT-587 in Healthy Subjects

NCT07728487 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2026-07-27

No results posted yet for this study

Summary

This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-587 in healthy subjects

Conditions

  • Hepatitis E

Interventions

DRUG

AT-587

Parallel Assignment

OTHER

Placebo

Parallel Assignment

Sponsors & Collaborators

  • Atea Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-13
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07728487 on ClinicalTrials.gov